SPYRE THERAPEUTICS, INC. Derivative Liability
SPYRE THERAPEUTICS, INC. (SYRE) had Derivative Liability of $38.62 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2026-08-04
- 2026-06-30: Derivative Liability $38.62M.
- 2026-03-31: Derivative Liability $56.95M.
- 2025-12-31: Derivative Liability $26.68M.
- 2024-12-31: Derivative Liability $61.70M.
| Period end | Derivative Liability |
|---|---|
| 2026-06-30 | $38.62M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $56.95M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $26.68M 10-Q · filed 2026-08-04 |
| 2024-12-31 | $61.70M 10-K · filed 2026-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |